IL-33 protects mice against dss-induced chronic colitis by increasing both regulatory B cell and regulatory T cell responses as well as decreasing Th17 Cell response

Journal of Immunology Research

Volumn 2018, Issue , 2018, Pages

  Zhu, Jun feng ^a   Xu, Ying ^a   Zhao, Jian ^a,b   Li, Xue ^a   Meng, Xinrui ^a   Wang, Tian qi ^a   Zou, Ben yao ^a   Zhao, Peng yan ^a   Liu, Qi ^a   Lu, Chang long ^c   Zheng, Fang liang ^a   Liu, Hong sheng ^a,b,d  

^a LIAONING UNIVERSITY   (China)

^b Engineering Laboratory for Molecular Simulation and Designing of Drug Molecules of Liaoning   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d Research Center for Computer Simulating and Information Processing of Bio macromolecules of Liaoning   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; PROTECTIVE AGENT; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 33; UNCLASSIFIED DRUG; IL33 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE SUBPOPULATION; C57BL 6 MOUSE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEXTRAN SULFATE SODIUM-INDUCED COLITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY B LYMPHOCYTE; REGULATORY T LYMPHOCYTE; SYMPTOM; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TISSUE SECTION; ANIMAL; C57BL MOUSE; COLITIS; DISEASE MODEL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; B-LYMPHOCYTES, REGULATORY; CHRONIC DISEASE; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-33; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 85058590342     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2018/1827901     Document Type: Article

References (67)

1. W. T. Uniken Venema, M. D. Voskuil, G. Dijkstra, R. K. Weersma, and E. A. Festen, “The genetic background of inflammatory bowel disease: from correlation to causality,” The Journal of Pathology, vol. 241, no. 2, pp. 146–158, 2017.
2. Obermeier, Kojouharoff, Hans, Schölmerich, Gross, and Falk, “Interferon-gamma (IFN-γ)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice,” Clinical and Experimental Immunology, vol. 116, no. 2, pp. 238–245, 1999.
3. C. Bauer, P. Duewell, C. Mayer et al., “Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome,” Gut, vol. 59, no. 9, pp. 1192–1199, 2010.
4. F. Sanchez-Muñoz, A. Dominguez-Lopez, and J. K. Yamamoto-Furusho, “Role of cytokines in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4280–4288, 2008.
5. S. Melgar, A. Karlsson, and E. Michaëlsson, “Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 288, no. 6, pp. G1328–G1338, 2005.
6. K. J. Maloy and F. Powrie, “Intestinal homeostasis and its breakdown in inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 298–306, 2011.
7. A. Mizoguchi, E. Mizoguchi, and A. K. Bhan, “The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor α mutant mice,” Gastroenterology, vol. 116, no. 2, pp. 320–326, 1999.
8. F. Heller, P. Florian, C. Bojarski et al., “Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution,” Gastroenterology, vol. 129, no. 2, pp. 550–564, 2005.
9. H. Takedatsu, K. S. Michelsen, B. Wei et al., “TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation,” Gastroenterology, vol. 135, no. 2, pp. 552–567.e2, 2008.
10. D. Fina, M. Sarra, M. C. Fantini et al., “Regulation of gut inflammation and Th17 cell response by interleukin-21,” Gastroenterology, vol. 134, no. 4, pp. 1038–1048.e2, 2008.
11. X. Sun, H. Yamada, K. Shibata et al., “CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses,” The Journal of Immunology, vol. 185, no. 12, pp. 7671–7680, 2010.
12. J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, vol. 23, no. 5, pp. 479–490, 2005.
13. C. Moussion, N. Ortega, and J. P. Girard, “The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?,” PLoS One, vol. 3, no. 10, article e3331, 2008.
14. V. Carriere, L. Roussel, N. Ortega et al., “IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 282–287, 2007.
15. A. M. Miller, D. Xu, D. L. Asquith et al., “IL-33 reduces the development of atherosclerosis,” The Journal of Experimental Medicine, vol. 205, no. 2, pp. 339–346, 2008.
16. A. A. Chackerian, E. R. Oldham, E. E. Murphy, J. Schmitz, S. Pflanz, and R. A. Kastelein, “IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex,” The Journal of Immunology, vol. 179, no. 4, pp. 2551–2555, 2007.
17. S. Ali, M. Huber, C. Kollewe, S. C. Bischoff, W. Falk, and M. U. Martin, “IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18660–18665, 2007.
18. C. J. Beltrán, L. E. Núñez, D. Díaz-Jiménez et al., “Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 16, no. 7, pp. 1097–1107, 2010.
19. A. Kobori, Y. Yagi, H. Imaeda et al., “Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis,” Journal of Gastroenterology, vol. 45, no. 10, pp. 999–1007, 2010.
20. L. Pastorelli, R. R. Garg, S. B. Hoang et al., “Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 17, pp. 8017–8022, 2010.
21. A. Latiano, O. Palmieri, L. Pastorelli et al., “Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease,” PLoS One, vol. 8, no. 4, article e62144, 2013.
22. M. A. K. Sedhom, M. Pichery, J. R. Murdoch et al., “Neutrali-sation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice,” Gut, vol. 62, no. 12, pp. 1714–1723, 2013.
23. R. Rani, A. G. Smulian, D. R. Greaves, S. P. Hogan, and D. R. Herbert, “TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function,” European Journal of Immunology, vol. 41, no. 7, pp. 2000–2009, 2011.
24. P. N. Pushparaj, D. Li, M. Komai-Koma et al., “Interleukin-33 exacerbates acute colitis via interleukin-4 in mice,” Immunology, vol. 140, no. 1, pp. 70–77, 2013.
25. A. Waddell, J. E. Vallance, P. D. Moore et al., “IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function,” Inflammatory Bowel Diseases, vol. 21, no. 12, pp. 2737–2746, 2015.
26. P. Groβ, K. Doser, W. Falk, F. Obermeier, and C. Hofmann, “IL-33 attenuates development and perpetuation of chronic intestinal inflammation,” Inflammatory Bowel Diseases, vol. 18, no. 10, pp. 1900–1909, 2012.
27. + regulatory T-cell responses in mice,” Molecular Medicine, vol. 18, pp. 753–761, 2012.
28. J. Zhu, Y. Wang, F. Yang et al., “IL-33 alleviates DSS-induced chronic colitis in C57BL/6 mice colon lamina propria by suppressing Th17 cell response as well as Th1 cell response,” International Immunopharmacology, vol. 29, no. 2, pp. 846–853, 2015.
29. J. Zhu, Y. Xu, C. Zhu et al., “IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis,” International Immunopharmacology, vol. 46, pp. 38–47, 2017.
30. A. K. Knight, A. B. Blázquez, S. Zhang, L. Mayer, H. A. Sampson, and M. C. Berin, “CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 293, no. 6, pp. G1234–G1243, 2007.
31. M. C. Pils, A. Bleich, I. Prinz et al., “Commensal gut flora reduces susceptibility to experimentally induced colitis via T-cell-derived interleukin-10,” Inflammatory Bowel Diseases, vol. 17, no. 10, pp. 2038–2046, 2011.
32. X. Wang, Y. Zhu, M. Zhang, H. Wang, Y. Jiang, and P. Gao, “Ulcerative colitis is characterized by a decrease in regulatory B cells,” Journal of Crohn's and Colitis, vol. 10, no. 10, pp. 1212–1223, 2016.
33. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5,” The Journal of Immunology, vol. 157, no. 3, pp. 1261–1270, 1996.
34. G. M. Cobrin and M. T. Abreu, “Defects in mucosal immunity leading to Crohn’s disease,” Immunological Reviews, vol. 206, no. 1, pp. 277–295, 2005.
35. S. R. Targan and L. C. Karp, “Defects in mucosal immunity leading to ulcerative colitis,” Immunological Reviews, vol. 206, no. 1, pp. 296–305, 2005.
36. Reg cell lineages: a (co-)evolutionary perspective,” Nature Reviews Immunology, vol. 9, no. 12, pp. 883–889, 2009.
37. Y. L. Jones-Hall and M. B. Grisham, “Immunopathological characterization of selected mouse models of inflammatory bowel disease: comparison to human disease,” Pathophysiol-ogy, vol. 21, no. 4, pp. 267–288, 2014.
38. I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya, “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice,” Gastroenterology, vol. 98, no. 3, pp. 694–702, 1990.
39. M. Okamura, K. Yoh, M. Ojima, N. Morito, and S. Takahashi, “Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis,” Experimental Animals, vol. 63, no. 2, pp. 133–140, 2014.
40. L. Liu, H. Li, H. Zhang et al., “Tu1947 1,25-dihydroxyvitamin D3 regulates the development of chronic colitis by modulating both T helper (Th)1 and TH17 activation,” Gastroenterology, vol. 142, no. 5, article S-884, 2012.
41. H. R. Jiang, M. Milovanović, D. Allan et al., “IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages,” European Journal of Immunology, vol. 42, no. 7, pp. 1804–1814, 2012.
42. M. Barbour, D. Allan, H. Xu et al., “IL-33 attenuates the development of experimental autoimmune uveitis,” European Journal of Immunology, vol. 44, no. 11, pp. 3320–3329, 2014.
43. Y. Luo, Y. Zhou, W. Xiao et al., “Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response,” Brain Research, vol. 1597, no. 2, pp. 86–94, 2015.
44. + T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006.
45. P. P. Ahern, C. Schiering, S. Buonocore et al., “Interleukin-23 drives intestinal inflammation through direct activity on T cells,” Immunity, vol. 33, no. 2, pp. 279–288, 2010.
46. + regulatory T cells in immunological tolerance to self and non-self,” Nature Immunology, vol. 6, no. 4, pp. 345–352, 2005.
47. C. G. Mayne and C. B. Williams, “Induced and natural regulatory T cells in the development of inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 19, no. 8, pp. 1772–1788, 2013.
48. D. Burzyn, C. Benoist, and D. Mathis, “Regulatory T cells in nonlymphoid tissues,” Nature Immunology, vol. 14, no. 10, pp. 1007–1013, 2013.
49. high T cells in inflammatory bowel disease,” Gastroenterology, vol. 128, no. 7, pp. 1868–1878, 2005.
50. A. Yamada, R. Arakaki, M. Saito, T. Tsunematsu, Y. Kudo, and N. Ishimaru, “Role of regulatory T cell in the pathogenesis of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 22, no. 7, pp. 2195–2205, 2016.
51. D. Unutmaz and B. Pulendran, “The gut feeling of Treg cells: IL-10 is the silver lining during colitis,” Nature Immunology, vol. 10, no. 11, pp. 1141–1143, 2009.
52. B. M. Matta and H. R. Turnquist, “Expansion of regulatory T cells in vitro and in vivo by IL-33,” Methods in Molecular Biology, vol. 1371, pp. 29–41, 2016.
53. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients,” Immunity, vol. 32, no. 1, pp. 129–140, 2010.
54. A. Das, G. Ellis, C. Pallant et al., “IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection,” The Journal of Immunology, vol. 189, no. 8, pp. 3925–3935, 2012.
55. + T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells,” Autoimmunity Reviews, vol. 11, no. 9, pp. 670–677, 2012.
56. A. Hahn, N. Thiessen, R. Pabst, M. Buettner, and U. Bode, “Mesenteric lymph nodes are not required for an intestinal immunoglobulin A response to oral cholera toxin,” Immunology, vol. 129, no. 3, pp. 427–436, 2010.
57. A. Mizoguchi, E. Mizoguchi, H. Takedatsu, R. S. Blumberg, and A. K. Bhan, “Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation,” Immunity, vol. 16, no. 2, pp. 219–230, 2002.
58. Y. Mishima, S. Ishihara, M. M. Aziz et al., “Decreased production of interleukin-10 and transforming growth factor-β in Toll-like receptor-activated intestinal B cells in SAMP1/Yit mice,” Immunology, vol. 131, no. 4, pp. 473–487, 2010.
59. A. Oka, S. Ishihara, Y. Mishima et al., “Role of regulatory B cells in chronic intestinal inflammation: association with pathogenesis of Crohn’s disease,” Inflammatory Bowel Diseases, vol. 20, no. 2, pp. 315–328, 2014.
60. K. Yanaba, A. Yoshizaki, Y. Asano, T. Kadono, T. F. Tedder, and S. Sato, “IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model,” The American Journal of Pathology, vol. 178, no. 2, pp. 735–743, 2011.
61. M. Nanno, Y. Kanari, T. Naito et al., “Exacerbating role of γδ T cells in chronic colitis of T-cell receptor α mutant mice,” Gastroenterology, vol. 134, no. 2, pp. 481–490, 2008.
62. T. Tsuchiya, S. Fukuda, H. Hamada et al., “Role of gamma delta T cells in the inflammatory response of experimental colitis mice,” The Journal of Immunology, vol. 171, no. 10, pp. 5507–5513, 2003.
63. + Treg cells inhibit human memory γδ T cells to produce IFN-γ in response to M tuberculosis antigen ESAT-6,” Blood, vol. 111, no. 12, pp. 5629–5636, 2008.
64. S. Gordon and F. O. Martinez, “Alternative activation of macrophages: mechanism and functions,” Immunity, vol. 32, no. 5, pp. 593–604, 2010.
65. S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2003.
66. A. Arranz, C. Doxaki, E. Vergadi et al., “Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 24, pp. 9517–9522, 2012.
67. L. Tu, J. Chen, D. Xu et al., “IL-33-induced alternatively activated macrophage attenuates the development of TNBS-induced colitis,” Oncotarget, vol. 8, no. 17, pp. 27704–27714, 2017.